Iconovir Bio
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
689 5th Ave Fl 12, New York City, New Yo...Phone Number
(858) 922-9594Website
www.iconovir.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Iconovir Bio
IconOVir Bio is dedicated to advancing cancer treatment with the mission to cure cancer and restore life to every patient globally. The company focuses on innovative solutions in the biopharmaceutical sector. Their intended clients include cancer patients and healthcare providers seeking effective therapies. IconOVir Bio is committed to pushing the boundaries of cancer research and treatment.Explore more
Iconovir Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Iconovir Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Iconovir Bio has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Iconovir Bio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Iconovir Bio
Click to see if Iconovir Bio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Iconovir Bio has new funding data
Iconovir Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Iconovir Bio recently announced quarterly report
Product Launch: Get notified when Iconovir Bio launches new products
Recommended Actions
Reach out to Masked Content who joined Iconovir Bio as Masked Content
Find 2 more new buyers
Compare Similar Companies to Iconovir Bio
Compare insights from companies similar to Iconovir Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Iconovir Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Iconovir Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Iconovir Bio.
Iconovir Bio financials insights
Gather financial insights about Iconovir Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$77M
Iconovir Bio Tech Stack
A closer look at the technologies used by Iconovir Bio
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Board of Directors
Event
Events
Event
Events
Iconovir Bio News & Media
IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042
SAN DIEGO, Calif.--(BUSINESS WIRE)--IconOVir Bio, Inc. (IconOVir), a clinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that the first patient has been dosed in a Phase 1 dose escalation and expansion clinical trial evaluating intravenously (IV) administered ICVB-1042 for the treatment of advanced solid tumors. “We are delighted to begin clinical evaluation of ICVB-1042, our potentIconOVir Bio to Present at Jefferies Healthcare Conference
SAN DIEGO, Calif.--(BUSINESS WIRE)--IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 4:30 p.m. ET (1:30 p.m. PT). About IconOVir IconOVir is a preclinical-stagIconOVir Bio to Present at Oppenheimer 33rd Annual Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 4:40 p.m. ET (1:40 p.m. PT). About IconOVir IconOVir is a preclinicaIconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022
SAN DIEGO--(BUSINESS WIRE)--IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced new preclinical data demonstrating proof-of-concept for its lead program ICVB-1042. ICVB-1042 is an oncolytic adenovirus (Ad), rationally designed with genomic modifications to confer tumor selective replication and enhanced tumor cell killing, as well as allow for eit
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Iconovir Bio
Sign Up For FreeTo access detailed company insights
IconOVir Bio is dedicated to advancing cancer treatment with the mission to cure cancer and restore life to every patient globally. The company focuses on innovative solutions in the biopharmaceutical sector. Their intended clients include cancer patients and healthcare providers seeking effective therapies. IconOVir Bio is committed to pushing the... Read More
